Clinical pharmacology and pharmacokinetics of antiretrovirals in Asia

Asian Biomedicine

Volumn 3, Issue 1, 2009, Pages 53-62

  Lugt, Jasper Van Der ^a,b,c   Avihingsanon, Anchalee ^a  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b International Antiviral Therapy Evaluation Center   (Netherlands)

^c NONE   (Thailand)

Author keywords

Asia; HIV; NNRTI; Pharmacokinetics; Protease inhibitors

Indexed keywords

ATAZANAVIR; DIDANOSINE; EFAVIRENZ; GPO VIR S30; INDINAVIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; ASIA; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTOXICATION; ETHNIC DIFFERENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; NEPHROTOXICITY; POPULATION RESEARCH; PRACTICE GUIDELINE; PREGNANCY; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; THIRD TRIMESTER PREGNANCY; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 70349335882     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (London, England). 2001;15:71-75 (Pubitemid 32055781)
2. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (London, England). 2001;15:1089-1095
3. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS (London, England). 2002;16 (SUPPL. 1):S5-37.
4. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of linical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007;8:679-688
5. Ruxrungtham K, Kroon ED, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, et al. A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviralnaive, HIV-infected Thai patients. AIDS (London, England). 2000;14:1375-1382
6. Duncombe C; Kerr S; Aviningsanon A, et al. Efficacy and tolerability of zidovudine 200 mg BID as part of combination antiretroviral therapy for 96 weeks. Presented at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney; 2007.
7. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, et al. Plasma nevirapine levels and 24-week efficacy in HIVinfected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006 Jul; 43:253-255
8. Manosuthi W, Kiertiburanakul S, Chaovavanich A, Sungkanuparph S. Plasma nevirapine levels and 24- week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among hai HIVinfected patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2007;90: 244-250 (Pubitemid 46377159)
9. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007; 44:141-144 (Pubitemid 44969000)
10. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antiviral therapy. 2005;10:937-943
11. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antiviral therapy. 2008; 13:529-536
12. ® (nevirapine) tablets 200 mg. 1996.
13. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first- line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253-1263
14. Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including regnant women. HIV medicine. 2007;8:357-366
15. Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS (London, England). 2005;19:1495-1499
16. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV medicine. 2008;9:214-220
17. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS (London, England). 2006;20:131-132
18. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS (London, England). 2005;19:1481-1486
19. Avihingsanon A, van der Lug J, M Gorowara M, Pboonrak S. A low dose of efavirenz provides adequate efavirenz plasma concentrations in Thai HIV-1 infected adults. Presented at AIDS 2008 - XVII International AIDS Conference. Mexico City; 2008.
20. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez- Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;40:1358-1361
21. Thanyawee Puthanakit PT, Linda Aurpibul,Tim R. Cressey, Virat Sirisanthana. Plasma efavirenz concentrations and the association with CYP2B6- 516G>T polymorphism in HIV- infected Thai children Antiviral therapy. 2008; in press.
22. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. Journal of acquired immune deficiency syndromes (1999). 2007; 45:133-136
23. Von Hentig N, Koenigs C, Elanjikal S, Linde R, Dunsch D, Kreuz W, et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. European journal of medical research. 2006;11:377-380
24. Cawthorne P, Ford N, Limpananont J, Tienudom N, Purahong W. WHO must defend patients' interests, not industry. Lancet. 2007;369:974-975
25. Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immun Defic Syndrom (1999). 2007;44:401-410
26. Van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicr Chemother. 2008;61:1145-1153
27. ® (lopinavir/ritonavir) tablets (lopinavir/ ritonavir) oral solution. 2007.
28. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside- pretreated children. Pediat Infect Dis J. 2005;24:874-879
29. Pope Kosalaraksa TB, Chulapan Engchanil, Pitch Boonrak et al. Double boosted protease inhibitors, saquinavir and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediat Infect Dis J 2008; in press.
30. Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, et al. Pharmacokinetics of highdose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrobial agents and chemotherapy. 2008;52:3276-3283
31. Van der Lugt Jasper; Puthanakit Thanyawee; Gorowara Meena; Bunupuradah Torsak, et al. Low-dose lopinavir/ritonavir provides adequate plasma concentrations in Thai HIV-infected children. Presented at 9th workshop on clinical pharmacology of HIV therapy. New Orleans; 2008.
32. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS (London, England). 2006;20:1931-1939
33. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, et al. Lopinavir exposure with an increased dose during pregnancy. J AIDS. 2008; in press.
34. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV medicine. 2005;6:421-425
35. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrobl Agen Chemother. 2000;44:2672-2678
36. Van der Lugt J, Gorowara M, Avihingsanon A, Sringam K, Wit F, Intasan J, et al. A 50-mg boosting dose of ritonavir generates adequate saquinavir plasma concentrations in Thai HIV-infected patients. Presented at CROI. Montreal; 2009.
37. Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, et al. A prospective study of efficacy and safety of once-daily saquinavir/ ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antiviral Therapy. 2005;10:761-767
38. Ananworanich J, Siangphoe U, Mahanontharit A, Hill A, Hirschel B, Ruxrungtham K. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Antiviral Therapy. 2004;9:1035-1036
39. Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/ 100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother. 2004;54:785-790
40. Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, et al. Pharmacokinetics of once-daily saquinavir/ ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antiviral Therapy. 2004; 9:423-429
41. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, et al. Interindividual variability of oncedaily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother. 2005; 56:908-913
42. Van der Lugt J, Hawkins D, van der Ende I, Vogel M, Wyen C, Colbers A, et al. Efficacy and pharmacokinetics of saquinavir boosted by ritonavir (1000/100mg BID) in pregnant HIV infected women. Presented at ICAAC/ IDSA. Washington DC; 2008.
43. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicr Chemother. 2003;51:1231-1238
44. Boyd MA, Siangphoe U, Ruxrungtham K, Reiss P, Mahanontharit A, Lange JM, et al. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicr Chemother. 2006;57:1161-1167
45. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antiviral therapy. 2005;10:301-307
46. Boyd MA, Siangphoe U, Ruxrungtham K, Duncombe CJ, Stek M, Lange JM, et al. Indinavir/ritonavir 800/ 100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV medicine. 2005;6:410-420
47. Gorowara M; Avihingsanon A; van der Lugt J, et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in Thai HIV-1 infected adults. Presented at 9th workshop on clinical pharmacology of HIV therapy. New Orleans; 2008.
48. Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicr Agent Chemother. 2006;50: 3336-3342
49. Von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavirboosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol. 2007;63:935-940
50. Chetchotisakd P, Anunnatsiri S. Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand. J AIDS (1999). 2008; 49:230-231
51. Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, et al. Atazanavir plus low- dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS (London, England). 2007;21:2409-2415